только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 3 / 3
Страница 1 / 2

Список литературы

  1. Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009;23:167–179.
  2. Meyer G, Hackemann A, Penna-Martinez M, Badenhoop K. What affects the quality of life in autoimmune Addison’s disease? Horm Metab Res. 2013;45:92–95.
  3. Chakera AJ, Vaidya B. Addison disease in adults: diagnosis and management. Am J Med. 2010;123:409–413.
  4. Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prevalence of Addison’s disease in German females: health insurance data 2008–2012. Eur J Endocrinol. 2014;170:367–373.
  5. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009;360:2328–2339.
  6. Мельниченко Г.А. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечебно-профилактическим мероприятиям при врожденной дисфункции коры надпочечников у пациентов во взрослом возрасте. Consilium Medicum. Consilium Medicum. (Прил.) 2016; 04: 8-19.
  7. Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93:4245–4253.

  1. LeeMK,Vasikaran S, Doery JC, Wijeratne N, Prentice D. Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study. Postgrad Med J. 2013;89:617–620.
  2. Cho HY, Kim JH, Kim SW, et al. Different cut-off values of the insulin tolerance test, the high-dose short Synacthen test (250 _g) and the low-dose short Synacthen test (1 _g) in assessing central adrenal insufficiency. Clin Endocrinol (Oxf). 2014;81:77–84.
  3. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 Feb;101(2):364-89.
  4. Gundgurthi A, Garg MK, Dutta MK, Pakhetra R. Intramuscular ACTH stimulation test for assessment of adrenal function. J Assoc Physicians India. 2013;61:320–324.
  5. Gagliardi L, Ho JT, Torpy DJ. Corticosteroid-binding globulin: the clinical significance of altered levels and heritable mutations. Mol Cell Endocrinol. 2010;316:24–34.
  6. Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf). 2013;78:497–502.
  7. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:4133–4160.
  8. El-Farhan N, Pickett A, Ducroq D, et al. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf). 2013;78:673–680.
  9. Дедов И.И., Мельниченко Г.А., Фадеев В.В. - Эндокринология- 3-е изд., перераб. и доп. - М.: Литтерра, 2015. - 412, [1] с.

  1. Baker PR, Baschal EE, Fain PR, et al. Haplotype analysis discriminates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison’s disease. J Clin Endocrinol Metab. 2010;95:E263–E270.
  2. Coco G, Dal Pra C, Presotto F, et al. Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies.J Clin Endocrinol Metab. 2006;91:1637–1645.
  3. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3:e289.
  4. Horn MA, Erichsen MM, Wolff AS, et al. Screening for X-linked adrenoleukodystrophy among adult men with Addison’s disease. Clin Endocrinol (Oxf). 2013;79:316–320.
  5. Ekman B, Bachrach-Lindström M, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ. A randomized, double-blind, crossover study comparing two- and four- dose hydrocortisone regimen with regard to quality of life, cortisol andACTHprofiles in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf). 2012;77: 18– 25.
  6. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord. 2012;12:8.
  7. Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012;97:473–481.
  8. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81–151.
  9. Methlie P, Husebye EE, Hustad S, Lien EA, Løvås K. Grapefruit juice and licorice increase cortisol availability in patients with Addison’s disease. Eur J Endocrinol. 2011;165:761–769.

  1. Ross IL, Bergthorsdottir R, Levitt N, et al. Cardiovascular risk factors in patients with Addison’s disease: a comparative study of South African and Swedish patients. PLoS One. 2014;9:e90768.
  2. Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison’s disease. Clin Endocrinol (Oxf). 2015;82:789–792.
  3. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015; 3:216–226.
  4. Allolio B. Extensive expertise in endocrinology: adrenal crisis. Eur J Endocrinol. 2015;172:R115–R124.
  5. Hahner S, Spinnler C, FassnachtM,et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab. 2015;100:407–416.
  6. Reisch N, Willige M, Kohn D, et al. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2012;167:35–42.
  7. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5_-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98:161–171.
  8. Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf). 2012;76:21–25.
  9. Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness.NEngl J Med. 2013;368:1477– 1488.
  10. Hahner S, Burger-Stritt S, Allolio B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol. 2013;169:147–154.

Для продолжения работы требуется вход / регистрация